News Quantified

RDHL – redhill biopharma ltd. - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Top News Gainers

3/13 RedHill Biopharma Announces Preferred Position for Talicia® on Express Scripts National Preferred Formulary Effective March 13, 2020 26.1%

4/2 RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca 12.6%

4/13 RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel 10.6%

4/20 Form 6-K RedHill Biopharma Ltd. For: Apr 20 10.5%

7/12 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at WBB Securities from a "buy" rating to a "strong-buy" rating. They now have a $17.00 price target on the stock. 8.2%

3/23 Form 6-K RedHill Biopharma Ltd. For: Mar 23 7.9%

4/6 RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use 7.7%

4/27 Form 6-K RedHill Biopharma Ltd. For: Apr 27 7.5%

3/4 RedHill Biopharma (RDHL) Q4 2019 Earnings Call Transcript [The Motley Fool] 6.3%

12/23 3 Stocks with Growth Prospects in the Triple Digits [Yahoo! Finance News] 4.6%

Top News Decliners

11/4 UPDATE 1-U.S. FDA approves RedHill's bacterial infection treatment [Yahoo! Finance News] -19.7%

3/11 Form 6-K RedHill Biopharma Ltd. For: Mar 11 -17.7%

2/27 RedHill Biopharma to Host Full-Year 2019 Financial Results Conference Call on March 4, 2020 -13.6%

10/11 RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease -13.5%

4/28 RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary -13.0%

3/9 Form 6-K RedHill Biopharma Ltd. For: Mar 09 -12.6%

7/22 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -12.1%

3/23 RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on March 26 -11.7%

3/17 REDHILL BIOPHAR/S (NASDAQ: RDHL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.75 price target on the stock. -10.5%

2/6 REDHILL BIOPHAR/S (NASDAQ: RDHL) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day